# Trial of Ateronon in Patients With Coronary Disease to Evaluate Its Effectiveness in Assessing the Risk Factors of Atherosclerosis

Study · id `cardio:ct-nct01287182` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01287182](<https://clinicaltrials.gov/study/NCT01287182>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT01287182

Browse, organ or system: Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 100 participants.

## Technical summary

Registry record NCT01287182. Non-randomized; no masking; primary purpose treatment. Start 2011-05 (registry gives no type); primary completion 2011-12 (actual). Results not posted.

## Key facts

- Design: Interventional study; non-randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 100 participants (enrolled count; ClinicalTrials.gov record NCT01287182, source copy `cardio:ctgov-nct01287182-2013-05-21`, retrieved 2026-10-31)
- Start date: 2011-05 (registry gives no type) (ClinicalTrials.gov record NCT01287182, source copy `cardio:ctgov-nct01287182-2013-05-21`, retrieved 2026-10-31)
- Primary completion: 2011-12 (actual) (ClinicalTrials.gov record NCT01287182, source copy `cardio:ctgov-nct01287182-2013-05-21`, retrieved 2026-10-31)
- Completion: 2011-12 (actual) (ClinicalTrials.gov record NCT01287182, source copy `cardio:ctgov-nct01287182-2013-05-21`, retrieved 2026-10-31)
- Countries: Lebanon (ClinicalTrials.gov record NCT01287182, source copy `cardio:ctgov-nct01287182-2013-05-21`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01287182-2013-05-21`, retrieved 2026-10-31)

## The registry's words

- Brief title: Trial of Ateronon in Patients With Coronary Disease to Evaluate Its Effectiveness in Assessing the Risk Factors of Atherosclerosis
- Condition: Atherosclerosis
- Intervention (Drug): Ateronon
- Lead sponsor: Omicron Pharmaceuticals
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Atherosclerosis (`cardio:atherosclerosis`)
- Registry lists this organization as the lead sponsor: Omicron Pharmaceuticals (`cardio:org-omicron-pharmaceuticals`)

## Provenance

Content hash: 33b98899c0ba41a183a223ec7687647baad7983f432d0a30d1b8c8115d36ade5
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
